INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 398,079 |
| Dec 13, 2013 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Dec 14, 2012 |
Director, EVP CSO Pres Regen Res Labs
Trans History: 617
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Feb 14, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 234,616 | $13.00 | 390,679 |
| Feb 14, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 234,616 | -- | 15,384 |
| Dec 15, 2003 |
Director, Chief Exec Officer & President
Trans History: 404
|
Director, Chief Exec Officer & President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 234,616 | -- | 234,616 |
| May 12, 2016 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 230,684 | $20.32 | 563,564 |
| May 12, 2016 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 230,684 | -- | 76,895 |
| Dec 17, 2012 |
Director, EVP CSO Pres Regen Res Labs
Trans History: 617
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 230,350 | $179.13 | 1,066,484 |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 617
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 222,000 | -- | 356,332 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.